Tobramycin

Tobramycin
Clinical data
Trade namesNebcin, Tobrex, Tobi, others
Other names47663, SPRC-AB01
AHFS/Drugs.comMonograph
MedlinePlusa682660
License data
Pregnancy
category
  • AU: D
Routes of
administration
Intravenous, intramuscular, inhalation, ophthalmic
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein bindingNot bound
MetabolismNot metabolized
Elimination half-life2–3 hrs
ExcretionExclusively via kidneys
Identifiers
  • (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.046.642
Chemical and physical data
FormulaC18H37N5O9
Molar mass467.520 g·mol−1
3D model (JSmol)
  • C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N
  • InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1 Y
  • Key:NLVFBUXFDBBNBW-PBSUHMDJSA-N Y
  (verify)

Tobramycin is an aminoglycoside antibiotic derived from Streptomyces tenebrarius that is used to treat various types of bacterial infections, particularly Gram-negative infections. It is especially effective against species of Pseudomonas.

It was patented in 1965, and approved for medical use in 1974. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 281st most commonly prescribed medication in the United States, with more than 600,000 prescriptions.